Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
63 results about "Lipid profile" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
<p>Normal results are infered when</p><ul><li>Total Cholesterol is < 200 mg/dL</li><li>LDL Choleterol is < 100 mg/dL, if you are diabetic or have CAD, < 70 mg/dL</li><li>Non HDL Cholesterol is < 130 mg/dL</li><li>Fasting Triglycerides is < 150 mg/dL</li></ul><p>Abnormal results and high lipids are inferred when:</p><ul><li>Total Cholesterol is ≥ 240 mg/dl</li><li>LDL Choleterol is between 160-189 mg/dL</li><li>HDL Cholesterol is > 60 mg/dL</li><li>Non HDL Cholesterol is between 190-219 mg/dL</li><li>Fasting Triglycerides is between 160-189 mg/dL</li></ul>
Methods and compositions for modification of lipid biosynthesis
The invention provides polypeptides having wax ester synthase and acyl-CoA:diacylglycerol acyltransferase activity. Also provided are the nucleic acids encoding such polypeptides, cells and organisms transformed therewith and methods of use thereof. The invention allows the modification of lipid profiles in host cells and organisms. Novel methods for the production of waxy esters are also provided by the invention.
Owner:MONSANTO TECH LLC
Reduced Pigmentation Microalgae Strains and Products Therefrom
InactiveUS20100297292A1Reduced colorationIncrease rangeMilk preparationDough treatmentHypopigmentationCarotenoid
The invention provides unique and novel strains of microalgae that have been subjected to non-transgenic methods of mutation sufficient to reduce the coloration of biomass produced by the strains. Biomass produced from such strains can be used in the manufacture of baked goods, gluten free foods, beverages, high lipid algal flours, and other foods. Pigments such as carotenoids and chlorophyll can be undesirable for consumer acceptance when incorporated into foods such as mayonnaise, yogurt, and white sauces that are not traditionally associated with colors such as yellow, red, orange and green. Some pigments, such as chlorophyll, can also create undesirable taste profiles. Use of reduced pigment microalgal biomass expands the range of food products that can be manufactured with healthy lipid profiles. High protein containing biomass of the invention, also reduced in pigmentation, is also incorporated into products such as meat analogues, nutritional bars and meal replacement beverages. The reduced pigmentation microalgae also allow for incorporation of higher amounts of biomass into certain food products that could otherwise be achieved using highly pigmented microalgal biomass. Methods of generating novel reduced pigment microalgae are disclosed herein. The strains provided by the invention are also useful in the manufacture of healthy, neutral colored extracted triglyceride oils.
Owner:TERRAVIA HLDG INC
Lipidomic Approaches to Determining Drug Response Phenotypes in Cardiovascular Disease
The present invention concerns the application of lipidomics to statin treatment for disorders such as cardiovascular disorders. Hence, the invention provides, among other things, a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject following commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The invention further provides a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject before commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen.
Owner:CHILDREN S HOSPITAL &RES CENT AT OAKLAN +4
Alteration of oil traits in plants
InactiveUS7157621B2Sugar derivativesMicrobiological testing/measurementGMO PlantsRegulatory sequence
The preparation and use of nucleic acid fragments useful in altering the oil phenotype in plants are disclosed. Chimeric construct incorporating such nucleic acid fragments and suitable regulatory sequences can be used to create transgenic plants having altered lipid profiles. Methods for altering the oil phenotype in plants using such nucleic acid fragments also are disclosed.
Owner:PIONEER HI BRED INT INC +1
Compositions and methods for producing elevated and sustained ketosis
ActiveUS9138420B2Rapid and sustained elevationImprove the level ofHydroxy compound active ingredientsMetabolism disorderSignificant elevationKetogenic diet
Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol / L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.
Owner:UNIV OF SOUTH FLORIDA
Lipid profile as a biomarker for early detection of neurological disorders
The present invention relates to compositions and methods for the early detection or monitoring of neurodegenerative diseases and neurological disorders including Alzheimer's disease. The invention provides biomarkers based on lipid profiles of biological samples and methods for using the biomarkers for the detection of neurodegenerative diseases and neurological disorders.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Food products for diabetics
Disclosed is a novel food product characterized by a low glucose or glucose free content, a balanced functional fat content, and a proactive agent aimed for the diabetic and diabetic-prone populations. The food product of the invention is a functional food which may be used clinically to lower the lipid level in people suffering from an imbalanced lipid profile and which may progress towards diabetes complications and coronary vascular disorders. In particular embodiments the proactive agent can be any of a naturally occurring lipid, a synthetic or mimetic lipid which is not digestible by humans and interferes with body weight gain / loss, plant extracts and substances derived therefrom, antioxidants, animal-derived substances, minerals and pharmaceuticals, and any mixture thereof.
Owner:ENZYMOTEC
Compositions and methods for producing elevated and sustained ketosis
ActiveUS20140350105A1Rapid and sustained elevationImprove metabolic healthBiocideHydroxy compound active ingredientsKetoneSignificant elevation
Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol / L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.
Owner:UNIV OF SOUTH FLORIDA
Diagnostic method for myopathy
This invention provides a diagnostic method for determining statin induced myopathy. The method is especially applicable for determining warnings, early signs and aiso symptomatic myopathy. The method inciudes coilecting a lipidomic profile from a biological sample such as blood or serum and comparing the obtained lipidomic profile to reference iipidomic markers. The reference iipidomic markers have been established by combining a pro-inflammatory muscle tissue gene expression profile with a iipidomic profile associated with high dosage statin treatment. This invention aiso relates to a kit for performing a method for determining statin induced myopathy.
Owner:ZORA BIOSCIENCES OY
Methods of sustaining dietary ketosis and its effects on lipid profile
ActiveUS20170172969A1Rapid and sustained elevationGood for healthMetabolism disorderOrganic chemistry methodsLipid formationDisease
The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (H2O) (n≧8). Days 1-28, rats received a daily 5 g / kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 μl) were acquired for analysis of glucose and βHB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until βHB returned to baseline. At day 1 and 28, 10 μL of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment. There were no significant changes in the lipid panel for any of the substances. There were significant reductions in body weight when animals were treated with either BD or KE as compared to control.
Owner:UNIV OF SOUTH FLORIDA
Gene combinations that alter the quality and functionality of soybean oil
InactiveUS6949698B2HydrolasesOther foreign material introduction processesBiotechnologyLipid formation
Novel gene combinations resulting in novel lipid profiles of soybean seeds and oil extracted from such seeds are disclosed. Methods for making such combinations are also described. In addition, the oils of this invention are disclosed to be useful in the manufacture of margarine and spread products.
Owner:EI DU PONT DE NEMOURS & CO
Food products for diabetics
Disclosed is a novel food product characterized by a low glucose or glucose free content, a balanced functional fat content, and a proactive agent aimed for the diabetic and diabetic-prone populations. The food product of the invention is a functional food which may be used clinically to lower the lipid level in people suffering from an imbalanced lipid profile and which may progress towards diabetes complications and coronary vascular disorders. In particular embodiments the proactive agent can be any of a naturally occurring lipid, a synthetic or mimetic lipid which is not digestible by humans and interferes with body weight gain / loss, plant extracts and substances derived therefrom, antioxidants, animal-derived substances, minerals and pharmaceuticals, and any mixture thereof.
Owner:ENZYMOTEC
Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
ActiveUS7833531B2Reduce food intake and body weightImproved profileAntibacterial agentsSenses disorderAgonistObesity
Owner:CENTOCOR
Lipid profile as a biomarker for early detection of neurological disorders
The present invention relates to compositions and methods for the early detection or monitoring of neurodegenerative diseases and neurological disorders including Alzheimer's disease. The invention provides biomarkers based on lipid profiles of biological samples and methods for using the biomarkers for the detection of neurodegenerative diseases and neurological disorders.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Lipid profile modulation
InactiveUS20050032761A1Altered cardiovascular risk profileLower Level RequirementsOrganic active ingredientsMetabolism disorderLipid regulation11β hsd1
The invention provides use of an agent which lowers levels of 11β-HSD1 in the manufacture of a composition for the promotion of an atheroprotective lipid profile.
Owner:THE UNIV OF EDINBURGH
Methods of sustaining dietary ketosis and its effects on lipid profile
InactiveUS20160317487A1Rapid and sustained elevationGood for healthMetabolism disorderOrganic chemistry methodsDiseaseLipid formation
Owner:UNIV OF SOUTH FLORIDA
Novel gene combinations that alter the quality and functionality of soybean oil
Novel gene combinations resulting in novel lipid profiles of soybean seeds and oil extracted from such seeds are disclosed. Methods for making such combinations are also described. In addition, the oils of the invention are disclosed to be useful in the manufacture of margarine and spread products.
Owner:EI DU PONT DE NEMOURS & CO
Marker screening method for beef origin place and application thereof
The invention relates to the field of beef origin place identification, in particular to a marker screening method for beef origin place and application thereof. The method comprises the following steps of: 1) using a chromatography-mass spectrometer to perform detection on lipid samples of the beef from different origin places; 2) analyzing the detection results by adopting a non-targeted lipid profile analysis and a principal component analysis; 3) performing significant difference analysis on the analysis results to obtain difference factors among lipids of the beef of different origin places; and 4) comparing the difference factors with a lipidomics database to obtain a marker. The screening method is based on the analysis of non-targeted lipidomics, and adopts the stoichiometry to analyze a difference marker. In this way, the markers selected by the method are used for identification of the origin place, and the method has high accuracy.
Owner:INST OF QUALITY STANDARD & TESTING TECH FOR AGRO PROD OF CAAS
Cannabinoid composition having an optimized fatty acid excipient profile
InactiveUS20190133992A1Superior sublingual and oral rate of deliveryIncrease concentrationHydroxy compound active ingredientsPharmaceutical delivery mechanismBiological bodyMedicine
A composition of matter for enhancing delivery of bioactive compounds, particularly cannabinoids into the human and animal organisms. The invention enhanced oral, transmucosal and transdermal delivery of a bioactive compound including cannabinoids through the use of an excipient having a desired ratio of fatty acids. The invention particularly includes a lipophilic phytocannabinoid such as THC or CBD, and an excipient fatty acid profile including palmitoleic acid and fatty acids selected from the group consisting of oleic acid and palmitic acid, and combinations thereof in optimal ratios. Macadamia nut oil is a preferred excipient having the desired lipid profile. Macadamia nut oil is a non-toxic plant oil, offers oxidation resistance to the fatty acids and cannabinoids to improve product shelf life, and has a sufficiently low melting temperature to remain liquid while refrigerated to further enhance product shelf life without changing the product phase from a liquid to a solid.
Owner:NOVOMATIC
Method for improving the carcass quality of an animal
InactiveUS7008664B1Improve carcass qualityFatty acid hydrogenationFatty acid esterificationBiotechnologyACP desaturase
A method for improving the carcass quality of an animal is described. This method invovles the preparation and use of nucleic acid fragments comprising all or substantially all of a corn oleosin promoter, a stearoyl-ACP desaturase and a delta-12 desaturase which can be used individually or in combination to modify the lipid profile of corn are described. Chimeric genes incorporating such nucleic acid fragments and suitable regulatory sequences can be used to create transgenic corn plants having altered lipid profiles are also described.
Owner:EI DU PONT DE NEMOURS & CO
Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis
InactiveUS20060182784A1Enhance dispersabilityImprove solubilityOrganic active ingredientsBiocideSerum igePlant sterol
The invention relates to a terapeutical composition comprising a protein hydrolysate and a plant sterol, wherein the weight ratio of the plant sterol to the protein hydrolysate is from 1:0.02 to 1:150. The invention also relates to a terapeutical composition comprising a protein hydrolysate and a synthetic emulsifier and / or a lipid based grain fraction having emulsifying properties. Said compositions can be used in a pharmaceutical, nutraceutical or food product for improving serum lipid profile.
Owner:RAISIO NUTRITION LTD
Pharmaceutical preparation for the alleviation of endometriosis
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17a-cyanomethyl-17ss-hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacetate or chlormadinonacetate at a daily dosage which is no more than two times the dosage required to suppress ovulation, together with one or a plurality of pharmaceutically acceptable adjuvants / carriers. The pharmaceutical composition according to the invention provides both the alleviation of endometriosis and the lack of a negative affect on bone metabolism and bone density, and is simultaneously able to keep the side effects known from conventional pharmaceuticals (such as hot flashes, acne, negative affects on the lipid profile) within tolerable limits. The pharmaceutical composition is thus suitable for long-term application.
Owner:BAYER SCHERING PHARMA OY
Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atheroscleroris
InactiveUS20100130401A1Good effectTo promote metabolismOrganic active ingredientsEdible oils/fats ingredientsPlant sterolSerum ige
Owner:RAISIO NUTRITION LTD
Lipid and growth trait genes
The present disclosure provides novel lipid and growth stress response target genes isolated from Chlamydomonas reinhardtii that when over expressed in an organism results in a change in the lipid profile, and / or lipid content, and / or growth of the organism. The present disclosure also describes organisms expressing the genes, and methods of using the novel genes to change the lipid content, lipid profile or growth of an organism.
Owner:SAPPHIRE ENERGY
Diagnostic method
The present invention relates to methods to identify one or more conditions in a subject. In particular, it relates to methods of identifying a condition such as cancer, which changes a lipid profile in a keratin-containing component of a subject, the changes to the lipid profile being determined by techniques such as chromatography and mass spectrometry.
Owner:SBC RES
Herbal composition
ActiveUS20200085904A1Effective in lipid profileArrest body weight gainDispersion deliveryMetabolism disorderPharmacologyType 2 Diabetes Mellitus
The present invention generally relates to an herbal composition effective in management of disorders related to metabolic syndrome. More particularly, the invention relates to an herbal composition effective in the management of disorders related to metabolic syndrome such as Type 2 diabetes mellitus, obesity and lipid profile management and a process for the preparation of such an herbal composition. The invention further relates to the use of the herbal composition in preparation of food supplements, pharmaceuticals and nutraceuticals for the management of disorders related to metabolic syndrome. The herbal composition effective in management of metabolic syndrome related disorders comprises of herbs selected from Curcuma longa, Emblica officinalis, Vernonia anthelmintica, Tinospora cordifolia, Trigonella foenum-graecum, Ixora coccinea and Syzygium cumini. Also provided is the use of herbal composition for the treatment of disorders related to metabolic syndrome. Also provided is a method of treating disorders related to metabolic syndrome comprising administering to a subject in need thereof a therapeutically effective amount of the herbal composition of the present invention.
Owner:KERALA AYURVEDA LTD INDIA +1
Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
InactiveCN101489546AOrganic active ingredientsHeavy metal active ingredientsCorosolic acidTert-leucine
Disclosed are combinations of soy protein, chromium and free leucine in amounts effective to inhibit the loss of lean body mass of a subject under conditions of caloric restriction. The soy protein, chromium and free leucine can be administered in several products, including a powder that is mixable into a liquid beverage (such as a shake), a snack bar, and a nutritional supplement (such as one or more tablets). Some embodiments also include corosolic acid and / or a tea drink that provides an effective dose of taurine. The products may be contained in kits containing the disclosed combinations as well as methods of using the products for weight loss and the inhibition of the loss of lean body mass in a subject during weight loss. The products and methods are also useful in the improvement of lipid profiles (for example reducing total cholesterol and LDL cholesterol levels).
Owner:SHAKLEE CORP
Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
The present invention concerns the application of lipidomics to statin treatment for disorders such as cardiovascular disorders. Hence, the invention provides, among other things, a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject following commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The invention further provides a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject before commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen.
Owner:CHILDREN S HOSPITAL &RES CENT AT OAKLAN +4
Use of long-acting glp-1 receptor agonists to improve insulin sensitivity and lipid profiles
ActiveUS20090098108A1Lose weightDecrease food intakeAntibacterial agentsOrganic active ingredientsLipid formationAgonist
The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the use of long acting GLP-1 receptor agonists to improve insulin sensitivity or lipid profiles in obesity and related therapeutic and / or diagnostic compositions, methods and devices.
Owner:CENTOCOR
Alteration of oil traits in plants
InactiveUS20070022499A1Sugar derivativesOther foreign material introduction processesLipid formationP PHENOTYPE
The preparation and use of nucleic acid fragments useful in altering the oil phenotype in plants are disclosed. Chimeric constructs incorporating such nucleic acid fragments and suitable regulatory sequences can be used to create transgenic plants having altered lipid profiles. Methods for altering the oil phenotype in plants using such nucleic acid fragments also are disclosed.
Owner:PIONEER HI BRED INT INC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com